"Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. "Sarepta's goal is to treat 100% of eligible individuals with DMD and using the best tools to enable earlier genetic-based identification of patients is a necessary element to eventually achieving that aspiration.
"Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться